Team

Paul Medeiros

Chief Executive Officer

Professional Bio

As Chief Executive Officer of Q-State Biosciences, Paul Medeiros is responsible for overseeing the company’s growth and sharpening its vision. He has nearly 25 years of global executive pharmaceutical experience with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. Prior to Q-State, Paul served as President and founding executive of Imbrium Therapeutics and directed the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment / accelerator firm Greenfield BioVentures. In addition to these roles, Paul has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Paul has also served on the boards of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. He received his AB with Honors from Brown University and his MBA from Columbia Business School.

Close Bio

Dr. Graham Dempsey

Chief Scientific Officer

Professional Bio

Graham Dempsey, Ph.D., leads Q-State’s research and development efforts. In this role, he oversees all internal development work and ensures successful execution of Q-State’s partnered programs with pharmaceutical companies and foundations. Graham began his scientific career at the University of Pennsylvania, developing novel single molecule methods for high sensitivity fluorescence measurements of molecular function. He then joined Harvard University where he developed a new super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM), allowing for multicolor, live-cell fluorescence imaging of biological samples with nanometer spatial resolution. The technique was commercialized by Nikon Instruments. Graham received a B.A. in Biochemistry and Physics from the University of Pennsylvania and a Ph.D. in Biophysics from Harvard University.

Close Bio

Kevin Coveney

Chief Financial Officer

Professional Bio

As Chief Financial Officer, Kevin oversees the company’s accounting, treasury, reporting, and FP&A functions. Kevin has deep corporate finance, treasury, and audit experience in the biotechnology and pharmaceutical industries, including more than a decade in public and private financial advisory roles. Before joining Q-State, Kevin served in a variety of senior management roles where he provided support for day-to-day operational management and execution of complex transactions. In addition to his corporate finance roles, he also held positions at Ernst & Young, BDO Seidman LLP, Marcum LLP, and Grant Thorton LLP rising to the level of Partner, serving in different assurance and consulting services capacities. Kevin is a CPA and holds a BSM in Management and Accounting from the University of Massachusetts Boston.

Close Bio

Wendell Taylor

Chief Business Officer

Professional Bio

Wendell Taylor leads business development efforts at Q-State. His responsibilities include identifying new opportunities for Q-State and leading the company through transactions that will drive business growth and create value. Wendell most recently served as the Vice President of Business Development and Head of Transactions at Vertex Pharmaceuticals, where he oversaw a broad range of acquisitions and collaborations across therapeutic areas and stages of development. Prior to his role at Vertex, Wendell spent 20 years as a partner at WilmerHale. His legal practice focused on advising national and international companies on corporate law matters, including mergers, acquisitions, and financings. While at WilmerHale, Wendell also served on the Executive and Hiring Committees and was co-chair of the firm’s Diversity Committee. Wendell has received numerous awards throughout his career and was selected as one of Boston Business Journal’s “40 under 40”. He has also taught courses on mergers and acquisitions at the Boston University School of Law and holds leadership positions at several non-profits in his community. Wendell earned a B.S. in biology and history from the College of William and Mary and a J.D. from the Boston University School of Law.

Close Bio

 

Michael LaCascia

Chief Legal Officer

Professional Bio

Michael LaCascia serves as Q-State’s Chief Legal Officer. In this role, he oversees Q-State’s legal functions, including licensing, transactions, compliance, and corporate governance. Michael joins Q-State from Vertex Pharmaceuticals, where he held several leadership roles within the company and was most recently Senior Vice President and General Counsel. Prior to serving in the corporate biotech industry, Michael spent 14 years as a partner at WilmerHale, an international law firm. He has also taught courses in mergers and acquisitions as an adjunct professor at Boston University School of Law. Michael earned an A.B. in economics from Harvard University and a J.D. from the Boston University School of Law.

Close Bio

Denise Johnson

VP, Human Resources & Operations

Professional Bio

Denise Johnson leads all human resources functions at Q-State. She has over 20 years of experience in a variety of areas, including developing HR processes and policies, compliance, employee relations, performance management, recruiting, benefits, compensation and training. Denise began her career at PriceWaterhouse (PwC) and KPMG, LLC. She then worked for 10 years as a consultant to early stage technology companies. She has held management and consulting positions with emerging growth companies in various industries including software, financial services, and life science organizations. Prior to joining Q-State, Denise established the HR infrastructure for Correlagen Diagnostics, Inc., a leading developer of genetic testing that assists physicians with early diagnosis for a more precise and tailored treatment. Denise earned her B.A. in English Literature with an advanced certificate in Human Resource Management from Northeastern University and is a member of the Society for Human Resource Management.

Close Bio

Dr. Owen McManus

Chief Technology Officer

Professional Bio

Owen McManus, Ph.D., is a drug discovery scientist with extensive experience in drug discovery, electrophysiology, and technology development. He worked for over twenty years at Merck Research labs where he led basic research teams at multiple discovery stages including target identification and validation, assay development, lead identification and optimization. These teams produced a number of clinical candidate compounds in multiple therapeutic areas. He was also Director of Operations at the Johns Hopkins Ion Channel Center, which provided HTS screening and lead optimization for ion channel and transporter targets for the academic community through the NIH Molecular Libraries program. He also worked as Director, Ion Channel Screening and Drug Discovery at Essen Bioscience, a leading instrument development company. At both Essen and Merck, he worked on development of novel instrumentation and technologies to support drug discovery, which have led to several marketed products. He is currently Chief Technology Officer at Q-State Biosciences working to advance Q-State technologies in drug discovery efforts.

Close Bio

Dr. David Gerber

Senior VP, Scientific Affairs

Professional Bio

Dr. David Gerber currently serves as a Senior Vice President of Scientific Affairs at Q-State and brings twenty years of experience in CNS disease biology and drug discovery to the company. Prior to joining Q-State, David was scientific co-founder and Vice President of Research at Galenea Corp., where he led discovery programs in schizophrenia, cognition and neurodegeneration, including several R&D collaborations with major pharmaceutical companies. A key aspect of this work included development and application of novel platform technology to directly target synaptic transmission for CNS drug discovery.  Before founding Galenea, as a postdoctoral fellow and Research Scientist in Susumu Tonegawa’s lab at MIT, his research focused on molecular and genetic factors involved in schizophrenia, and particularly on the potential link between calcineurin dysfunction and schizophrenia pathogenesis. David received a bachelor’s degree in mathematics and a Ph.D. in biology from the Massachusetts Institute of Technology.

Close Bio

Mette Smedegaard Andersen

VP, Strategy & Partnerships

Professional Bio

Mette Smedegaard Andersen joins Q-State from the Boston Consulting Group, where she was a Core Member of the Healthcare practice. Her work there centered on strategy development for Pharma and Biotech, ranging from R&D to drug launch and innovation strategies in companies across the US and Europe. Mette holds and M.B.A from the Harvard Business School, a MPhil in Nanotechnology from the University of Cambridge, and a B.A. in Chemistry and Physics from Harvard University. While at Harvard Business School, she studied business model innovations for precision medicine.

Close Bio